2.69
price up icon2.28%   0.06
after-market Dopo l'orario di chiusura: 2.75 0.06 +2.23%
loading
Precedente Chiudi:
$2.63
Aprire:
$2.6851
Volume 24 ore:
1.77M
Relative Volume:
0.46
Capitalizzazione di mercato:
$577.44M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-3.1113
EPS:
-0.8646
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
+5.91%
1M Prestazione:
+8.03%
6M Prestazione:
+75.82%
1 anno Prestazione:
+17.47%
Intervallo 1D:
Value
$2.68
$2.745
Intervallo di 1 settimana:
Value
$2.34
$2.745
Portata 52W:
Value
$1.05
$3.31

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Nome
Taysha Gene Therapies Inc
Name
Telefono
(214) 612-0000
Name
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Name
Dipendente
73
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TSHA's Discussions on Twitter

Confronta TSHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
2.69 687.82M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-11 Iniziato BofA Securities Buy
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-04-09 Iniziato Piper Sandler Overweight
2023-02-01 Downgrade Jefferies Buy → Hold
2023-01-27 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-11-09 Downgrade Goldman Buy → Neutral
2022-03-09 Iniziato Robert W. Baird Outperform
2022-03-01 Iniziato Wells Fargo Overweight
2022-02-18 Iniziato SMBC Nikko Outperform
2021-12-16 Iniziato Guggenheim Buy
2021-07-16 Iniziato Needham Buy
2021-06-24 Iniziato Truist Buy
2021-06-15 Iniziato BTIG Research Buy
2021-06-09 Iniziato Wedbush Outperform
2021-06-08 Iniziato JMP Securities Mkt Outperform
2021-05-19 Iniziato Cantor Fitzgerald Overweight
2021-05-11 Ripresa Jefferies Buy
2021-02-24 Iniziato William Blair Outperform
2021-01-05 Iniziato Oppenheimer Outperform
2020-10-19 Iniziato Chardan Capital Markets Buy
2020-10-19 Iniziato Goldman Buy
2020-10-19 Iniziato Jefferies Buy
2020-10-19 Iniziato Morgan Stanley Overweight
Mostra tutto

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

pulisher
Jul 23, 2025

What drives Taysha Gene Therapies Inc. stock priceUnrivaled growth potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Taysha Gene Therapies Inc. stockRapid wealth creation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Taysha Gene Therapies Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Taysha Gene Therapies Inc. a good long term investmentHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Jul 16, 2025
pulisher
Jul 15, 2025

Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Taysha Gene Therapies Inc. stock performs during market volatilityFree Popular Stock Recommendations - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated at Bank of America - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Biotech Bargains: Finding Gold in the Healthcare Sell-Off - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Taysha Gene's 5.9% Surge: A Deep Dive into the Unexplained Rally - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN

Jul 10, 2025
pulisher
Jul 08, 2025

Goldman Sachs Group Inc's Strategic Acquisition in Taysha Gene Therapies Inc - GuruFocus

Jul 08, 2025
pulisher
Jul 03, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

Taysha Gene Therapies (TSHA) Gets a Buy from Wells Fargo - The Globe and Mail

Jul 03, 2025
pulisher
Jul 01, 2025

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock - Nasdaq

Jul 01, 2025
pulisher
Jul 01, 2025

Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | TSHA Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 30, 2025

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data - MSN

Jun 30, 2025
pulisher
Jun 25, 2025

Rhumbline Advisers Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 25, 2025
pulisher
Jun 24, 2025

Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT - Yahoo Finance

Jun 24, 2025
pulisher
Jun 22, 2025

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to S&P Biotechnology Select Industry Index - MarketScreener

Jun 22, 2025
pulisher
Jun 14, 2025

Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus

Jun 10, 2025

Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):